These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design. Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators. Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916 [Abstract] [Full Text] [Related]
7. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators. J Am Coll Cardiol; 2019 Dec 10; 74(23):2858-2873. PubMed ID: 31806129 [Abstract] [Full Text] [Related]
8. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM Investigators. Eur Heart J; 2008 Dec 10; 29(24):3022-8. PubMed ID: 18987098 [Abstract] [Full Text] [Related]
11. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Circ Heart Fail; 2018 Jul 10; 11(7):e004962. PubMed ID: 29980595 [Abstract] [Full Text] [Related]
12. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. J Am Coll Cardiol; 2019 Aug 06; 74(5):601-612. PubMed ID: 31370950 [Abstract] [Full Text] [Related]
13. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Kasner M, Aleksandrov AS, Westermann D, Lassner D, Gross M, von Haehling S, Anker SD, Schultheiss HP, Tschöpe C. Int J Cardiol; 2013 Oct 12; 168(5):4652-7. PubMed ID: 23968714 [Abstract] [Full Text] [Related]
14. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM. Circ Heart Fail; 2016 Apr 12; 9(4):e002763. PubMed ID: 27056882 [Abstract] [Full Text] [Related]
15. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298 [Abstract] [Full Text] [Related]
16. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA, Kumbhani DJ. J Am Heart Assoc; 2015 Oct 12; 4(10):e002137. PubMed ID: 26459931 [Abstract] [Full Text] [Related]
17. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Park K, Park TH. Trials; 2016 Nov 03; 17(1):530. PubMed ID: 27809882 [Abstract] [Full Text] [Related]
18. Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis? Helske-Suihko S, Laine M, Lommi J, Kaartinen M, Werkkala K, Kovanen PT, Kupari M. J Cardiovasc Pharmacol; 2015 Mar 03; 65(3):233-40. PubMed ID: 25469804 [Abstract] [Full Text] [Related]
19. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV. JACC Heart Fail; 2019 May 03; 7(5):418-427. PubMed ID: 30981744 [Abstract] [Full Text] [Related]